Nipogalin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nipogalin

Property Description
Active Ingredient Cefuroxime
Pharmacological Class Second-generation cephalosporin antibiotic
Origin Semisynthetic
Dosage Forms Tablets, powder for solution/infusion
General Purpose To kill susceptible bacteria (bactericidal action)

What Type of Medicine is Nipogalin (Cefuroxime)?

Nipogalin is a prescription-only medicine whose identity is defined by its active ingredient, Cefuroxime. This substance is formally classified as a semisynthetic beta-lactam compound belonging to the second-generation cephalosporin antibiotic class. Cefuroxime is clinically recognized for its structural resilience, providing increased stability against certain bacterial defense mechanisms, such as enzymes known as beta-lactamases, compared to many older antibiotics. Other popular trade names that share the same active ingredient and formulation include Zinacef and Ceftin, confirming the ingredient's global use and recognition.


Composition, Forms, and General Purpose

The overall purpose of Nipogalin is to resolve bacterial illnesses by acting as a powerful bactericidal agent that directly eliminates susceptible pathogens. In its mechanism of action, Cefuroxime inhibits the essential final stage of bacterial cell wall synthesis, a critical process for the survival of the organism.

This compound is supplied in distinct dosage forms optimized for different uses and routes of administration. For oral use, such as the film-coated tablets and oral suspension, the chemical form used is Cefuroxime axetil. For parenteral use—meaning administration by injection or infusion—the drug is supplied as Cefuroxime sodium in powders for solution. This flexibility ensures the anti-infective agent can be effectively delivered in various medical scenarios, such as treating an established skin infection with convenient oral medication or a severe pneumonia requiring intravenous delivery.

What side effects are possible with Nipogalin?

Possible side effects and safety information

Nipogalin (Cefuroxime) has an officially documented safety profile, with potential effects categorized by frequency and the body's organ systems, as detailed in regulatory prescribing information.

Adverse Reactions by Frequency

The most Common adverse reactions listed in regulatory documents include diarrhoea, nausea, headache, dizziness, and an overgrowth of Candida. Effects classified as Uncommon include vomiting, skin rash, urticaria, and changes in blood counts like leukopenia.

Classification Examples of Officially Listed Effects
Common Headache, diarrhoea, nausea, Candida overgrowth
Uncommon Vomiting, skin rash, leukopenia, positive Coombs test

System-Organ Classes and Serious Reactions

Adverse effects are grouped into system-organ classes, primarily involving the Gastrointestinal Disorders, Blood and Lymphatic System Disorders, Immune System Disorders, and Nervous System Disorders.

Regulatory documents highlight Serious Adverse Reactions that include anaphylaxis (a severe allergic reaction), pseudomembranous colitis (a form of antibiotic-associated diarrhoea), and Severe Cutaneous Adverse Reactions (e.g., Stevens-Johnson syndrome).

Safety Constraints and Specific Populations

This medicine is contraindicated in individuals with a known severe hypersensitivity to cephalosporin antibiotics or a history of severe allergy to any other beta-lactam antibacterial agent, such as penicillins. Safety notes exist for renal impairment; as the medicine is cleared by the kidneys, the official label states that dosage adjustment is required in cases of marked impairment to reduce the risk of neurological effects, including seizures.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Nipogalin (Cefuroxime) strictly defines the overdose scenario based on potential Central Nervous System (CNS) toxicity and mandated emergency actions.


Documented Manifestations and Emergency Triggers

Overdose may manifest as seizures or convulsions, which are documented as serious clinical presentations resulting from cerebral irritation. Urgent medical help is mandated for specific, life-threatening outcomes. Immediate medical attention must be sought if the person has collapsed, is experiencing trouble breathing, or exhibits an inability to be awakened (unconsciousness). In all suspected cases, emergency services should be called, and the Poison Control Helpline must be contacted for guidance.

Management and Population-Specific Risk

Regulatory documentation states clearly that no specific antidote is known for this compound. Consequently, management relies on general symptomatic and supportive treatment provided in a supervised setting. The procedure of haemodialysis is officially documented as an available measure that can be used to effectively reduce the concentration of the compound in the bloodstream following overexposure. A key population-specific risk identified is the potential for drug accumulation in patients with impaired renal function due to the significantly slower excretion rate, which increases the likelihood of toxicity.

Therapeutic Uses of Nipogalin

This medication is considered relevant across conditions involving certain symptoms of the upper and lower respiratory systems, such as bacterial sinusitis, tonsillitis, and acute otitis media, which may present with noticeable discomfort. Nipogalin is generally considered relevant across domains where additional symptomatic support is needed, applicable within clinical settings that involve infections of the respiratory tract, ear, nose, throat, skin, soft tissues, and the uncomplicated urinary tract.


Support for Symptomatic Relief

Nipogalin assists with managing symptoms related to systemic imbalance, including fever and localized pain, and generally provides support that helps ease the overall symptom load during these periods. It is commonly used when short-term symptomatic assistance is needed, and supports the patient during difficult episodes by easing distress related to localized discomfort. The medication is also considered relevant in contexts involving heightened systemic burden, and may be applied in situations involving acute symptom patterns linked to severe infections or for addressing symptoms associated with early Lyme disease. It is applied in scenarios where additional management of discomfort is required, and assists with managing symptoms that create noticeable physiological strain.

“This medicine is relevant for managing symptoms that interfere with daily comfort and may be part of symptomatic management when groups of symptoms appear suddenly.”


Quick Fact: Relief for Localized Discomfort

Nipogalin is used to help address symptoms related to inflammatory or irritative states, and is relevant for easing localized discomfort and strain associated with bacterial infections in the skin, ear, and throat.

Regulatory References

  1. MedlinePlus overview on Cefuroxime

Eligibility and Restrictions for Use

The eligibility for Nipogalin is determined by regulatory agencies based on a patient’s medical history, age, and organ function, establishing clear conditions for use.

Contraindicated Populations

Nipogalin is strictly contraindicated for use in patients with a known hypersensitivity or allergy to cephalosporin antibiotics or a history of severe allergic reaction to any other beta-lactam antibacterial agent (e.g., penicillins).

Age-Related Eligibility

  • Adults and Adolescents (13 years and older) are eligible for most labeled uses.
  • Children aged 3 months to 12 years are approved for specific uses, often using the oral suspension form.
  • Infants younger than 3 months of age are considered a use-not-established population, as safety and effectiveness have not been confirmed by regulatory data.

Conditional Use and Restrictions

Use is restricted or conditional for certain patient groups:

  • Renal Impairment: Patients with markedly impaired renal function (e.g., Creatinine Clearance <20 mL/min) are eligible but require a mandatory reduction in the administered dose.
  • Gastrointestinal Disease: Caution is advised for individuals with a history of colitis or other gastrointestinal disease.
  • Phenylketonuria (PKU): The oral suspension formulation contains phenylalanine (aspartame) and is restricted in patients with PKU.

Physiological Status

During pregnancy, use should be considered only if clearly needed. The active ingredient is present in human milk in low quantities during lactation, requiring consideration of potential effects on the infant.

What should I know about interactions with other medicines?

Nipogalin (Cefuroxime) interacts with certain medicines and products through pharmacokinetic and pharmacodynamic mechanisms as documented in regulatory labeling.

Interactions Affecting Exposure

Co-administration with agents that reduce stomach acidity, such as Antacids, H2-Antagonists, or Proton Pump Inhibitors, significantly lowers the oral absorption and reduces the systemic bioavailability of Nipogalin. To counteract this pharmacokinetic effect, official regulatory documents require the administration of oral Cefuroxime to be separated from antacids by at least one hour before or two hours after the acid-reducing agent. The co-administration of Probenecid causes a direct interaction by inhibiting renal tubular secretion, which results in increased and prolonged plasma concentrations of Cefuroxime by reducing its clearance. Conversely, administration of the oral form with food increases its absorption and overall exposure.

Interactions Affecting Risk


A pharmacodynamic interaction exists with Oral Anticoagulants (such as Warfarin), which may increase the risk of bleeding or a documented fall in prothrombin activity. Co-administration with other nephrotoxic agents, including Aminoglycosides or Potent Diuretics, carries an increased, documented risk of nephrotoxicity. Furthermore, official regulatory information states that Nipogalin may decrease the effectiveness of certain Oral Contraceptives. These interaction patterns are noted to be particularly relevant in patients with underlying renal or hepatic impairment.

Mechanism of Action

How Nipogalin Works: Mechanism of Action

Nipogalin (Cefuroxime) functions as a bactericidal agent by interacting with the essential structural integrity of susceptible bacteria. Its action is purely focused on molecular processes unique to the pathogen.


Inhibiting the Bacterial Cell Wall Pathway

Cefuroxime's primary action is the irreversible inhibition of specific Penicillin-Binding Proteins (PBPs), particularly PBP-3, which are bacterial enzymes required for peptidoglycan cross-linking. This targets the fundamental molecular assembly of the bacterial cell wall.


Causing Cellular Lysis and Destruction

By preventing the completion of the rigid cell wall structure, the molecule initiates a destructive cascade. The resulting weak wall cannot withstand the high internal osmotic pressure of the cell, leading to autolysis and catastrophic cell rupture (lysis). This physiological effect results in the drug's bactericidal action against susceptible organisms.


Mechanistic Constraints by Bacterial Defense

The mechanism's functional scope is limited when bacteria develop resistance mechanisms, primarily the production of beta-lactamase enzymes that chemically destroy the Cefuroxime molecule before it can reach the PBP targets. Mutations that alter PBP structure also constrain the drug's effective binding affinity.

Dosage and Administration Information

How to Use Nipogalin (Cefuroxime) Administration Guidelines

Nipogalin (Cefuroxime) is administered only via injection or infusion. The route and frequency of administration are defined to ensure the intended application.

Administration Routes and Preparation

Administration is parenteral via:

  • Intravenous (IV) Injection: Administered as a bolus over 3 to 5 minutes, or via an infusion over 30 to 60 minutes.
  • Intramuscular (IM) Injection: Administered deeply into a large muscle mass.

The powdered medicine must first be reconstituted (mixed with water for injection) according to specific volume requirements for the chosen route. Doses larger than 1.5 g must be administered intravenously only, and no more than 750 mg should be injected at a single IM site.

Dosing and Frequency

Dosage and frequency are based on the patient's condition and weight, often administered on a regular schedule (e.g., every 8 hours). Example frequencies include:

Condition Typical Adult Dosing and Frequency
Common Infections 750 mg every 8 hours
Severe Infections 750 mg or 1.5 g every 6 to 8 hours

Population-Specific Rules

The administration schedule and dose amount require adjustment for patients with reduced kidney function (renal impairment). The dose is lowered based on creatinine clearance, and patients undergoing haemodialysis must receive a 750 mg dose immediately after each dialysis session. For children under 40 kg, the dosage is determined by weight, given in 2, 3, or 4 divided doses daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nipogalin (Cefuroxime)

Research into Nipogalin was structured around Randomized Controlled Trials (RCTs) and comparative studies for conditions like Acute Otitis Media (AOM) and Acute Bacterial Sinusitis. These studies were designed to examine outcomes related to physical discomfort and the status of clinical success or improvement in study participants, with findings describing patterns observed in the proportion of patients who met the study’s definition of a clinical success outcome.

For Lower Respiratory Tract Infections (such as pneumonia) and Uncomplicated Skin Infections, research included sequential therapy trials that tracked the transition from intravenous to oral administration in adults. Evidence is limited regarding outcomes in patients with severe infections, and some earlier trials utilized small sample sizes.

Special populations have been examined, particularly pediatric patients for ear and throat infections, with dedicated clinical trials exploring how symptoms change over time in younger age groups. However, safety and use have not been established in infants younger than three months of age.

Long-term follow-up is not fully established across all indications. Extended observation, typically up to a year, was primarily used in studies related to Early Lyme Disease to evaluate the long-term condition state and track whether the disease progressed. For most other conditions, studies focus on short-term and intermediate outcomes.

The scientific evidence points to areas where research is still emerging. For instance, evidence is limited regarding the effectiveness of Nipogalin against certain bacteria known to produce specific resistance mechanisms. The research provides context about group patterns but not individual predictions.

Key Studies & References Cefuroxime Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Nipogalin (FAQ)


Q: What happens if I miss a scheduled dose of Nipogalin?

A: If a dose of Nipogalin is missed, regulatory instructions recommend taking it as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose should be skipped entirely. It is important to return to the regular dosing schedule, and official guidance indicates that doubling the dose should be avoided.


Q: Can Nipogalin be taken on an empty stomach?

A: Official information for the film-coated tablet form of Nipogalin indicates that it can be taken with or without food. However, the oral suspension (liquid) form is generally recommended to be taken with food. Taking the oral forms with food typically helps to improve the absorption of the medicine.


Q: How long do any mild side effects from Nipogalin usually last?

A: The common and mild side effects of Nipogalin, such as nausea or diarrhea, are typically temporary. Regulatory documents indicate these effects often resolve on their own as the body adjusts to the medication or after the full course of treatment is completed.


Q: What supplements or vitamins are known to interact with Nipogalin?

A: While specific vitamins and general supplements are not listed as having documented interactions with Nipogalin in regulatory documents, certain agents like Probenecid can increase the amount of Nipogalin in the bloodstream. Patients are generally advised to inform their healthcare professional about all supplements, vitamins, and over-the-counter medicines being taken.


Q: Is Nipogalin safe for people who have kidney problems?

A: Yes, but use is conditional and requires clinical oversight. Because Nipogalin is cleared from the body by the kidneys, official product information indicates that the dosage requires reduction when kidney function is impaired. This adjustment is necessary to minimize the potential risk of side effects, including neurological issues.


Q: Is Nipogalin ever prescribed for children?

A: Yes, Nipogalin is approved for use in children. The medicine, often in the oral suspension form, is prescribed for specific bacterial infections in children aged 3 months to 12 years. Older children and adolescents are generally eligible for the tablet form.


Q: Does Nipogalin treat viral infections, like a cold or the flu?

A: No. Nipogalin is formally classified as a cephalosporin antibiotic, and its mechanism is solely focused on killing susceptible bacteria. Regulatory documents confirm that it is not effective against infections caused by viruses, such as the common cold or influenza (flu).


Q: Why do some people take Nipogalin for skin infections?

A: Nipogalin is officially indicated for the treatment of uncomplicated infections involving the skin and underlying soft tissues. It is effective because it targets common types of bacteria known to cause these issues, making it a viable option when an infection is caused by a susceptible organism.


Q: Can Nipogalin interact with herbal remedies or supplements?

A: Official regulatory labels do not list specific interactions with most common herbal remedies. However, official guidance recommends that patients inform their prescribing professional about all herbal products used, as many substances can affect drug absorption or metabolism.


Q: Is Nipogalin used to treat Lyme disease?

A: Yes, regulatory documents indicate that the oral tablet form of Nipogalin (Cefuroxime axetil) is an approved treatment option for patients diagnosed with early Lyme disease. This use is supported by specific clinical research and labeling.


Q: What if I vomit shortly after taking a dose of Nipogalin?

A: If vomiting occurs soon after taking a dose of Nipogalin, it is possible the medication may not have been fully absorbed. It is important to contact a healthcare professional immediately. A healthcare professional can provide guidance on whether a replacement dose is appropriate or if alternative action is needed.


Q: Can Nipogalin cause dizziness or affect my ability to drive?

A: Dizziness is a commonly reported side effect in official product information. Because Nipogalin can potentially cause central nervous system effects, particularly in patients with impaired kidney function, patients are advised to use caution when performing tasks that require mental alertness, such as driving or operating heavy machinery.


Q: How long does Nipogalin stay in your system after the last dose?

A: In adults with normal kidney function, the half-life of Cefuroxime is approximately 80 minutes (about 1.3 hours). This is the time it takes for half of the drug's concentration to be eliminated from the bloodstream. The medicine is primarily cleared from the body by the kidneys.


Q: Can I take other antibiotics at the same time as Nipogalin?

A: The injection form of Nipogalin is sometimes used concomitantly (at the same time) with other antimicrobials, such as aminoglycosides, in specific, severe clinical situations. However, co-administration with other medications requires evaluation by a healthcare professional, as some combinations, like with chloramphenicol, have been noted to potentially have antagonistic effects.


Q: Is a metallic taste in the mouth a possible side effect of Nipogalin?

A: Official side effect reports do not specifically name a 'metallic taste.' However, they do list less common effects that include an 'unusual or unpleasant change in taste.' If an abnormal taste is experienced, such effects should be noted and reported to a prescribing professional.


Q: What should I do if I notice white patches in my mouth while taking Nipogalin?

A: White patches in the mouth or throat may be a sign of a fungal infection, like Candida overgrowth, which is a common side effect of antibiotic treatment. Immediate contact with a healthcare provider is recommended for evaluation and appropriate management.


Q: Does Nipogalin affect the body's natural gut bacteria?

A: Yes. As with many antibacterial agents, Nipogalin can alter the normal bacteria that live in the colon. This change in the natural flora can sometimes lead to an overgrowth of certain bacteria, such as Clostridioides difficile, which is associated with diarrhea and colitis.


Q: Is there a risk of developing a secondary infection after taking Nipogalin?

A: Official warnings note a risk of developing a superinfection. This is a secondary infection that can occur when the antibiotic eliminates beneficial bacteria, allowing resistant fungal pathogens (like Candida) or other bacteria to grow. Patients should be monitored for signs of a new infection during and after therapy.


Q: Can Nipogalin cause changes in mood or sleep?

A: Adverse effects listed in the nervous system class include dizziness and somnolence (sleepiness). Changes in mood are not explicitly listed in common reports, but any unusual changes in mental status should be discussed with a healthcare provider.


Q: Why is Nipogalin sometimes taken for urinary tract infections (UTIs)?

A: Nipogalin (Cefuroxime axetil) is officially approved for treating uncomplicated urinary tract infections (UTIs). It is used for this purpose because it is effective against common strains of bacteria that cause these specific infections.


Q: Is it important to swallow the Nipogalin tablet whole, or can it be crushed?

A: The film-coated Nipogalin tablets are designed to be swallowed whole. Official information states that they should not be broken, crushed, or chewed, primarily because crushing the tablet releases a strong, persistent bitter taste and may also affect drug absorption.


Q: Why do some forums mention using Nipogalin for bite wounds?

A: Nipogalin is officially indicated for the treatment of bacterial infections of the skin and soft tissue. A healthcare professional may prescribe it for infected bite wounds if the responsible bacteria are susceptible to the medication, as this condition falls under the general scope of approved skin infections.


Q: What makes Nipogalin a 'second-generation' cephalosporin?

A: Nipogalin is classified as a second-generation cephalosporin due to its specific chemical properties. This structure gives it greater stability against beta-lactamase enzymes—bacterial defense mechanisms—compared to first-generation drugs. This allows it to be active against a broader range of Gram-negative bacteria.


Q: Is it possible to be allergic to Nipogalin if I'm not allergic to penicillin?

A: Yes, it is possible to be allergic to Nipogalin (a cephalosporin) even without a history of penicillin allergy. However, official warnings note a potential cross-sensitivity; individuals with a history of severe allergy to penicillin have experienced severe reactions when treated with cephalosporins. Nipogalin is strictly contraindicated if there is an allergy to any cephalosporin or other related beta-lactam antibiotic.

How should Nipogalin be stored and disposed of?

How to Store and Dispose of Nipogalin?

The official labeling for Nipogalin (Cefuroxime powder for solution for injection or infusion) defines specific storage and handling requirements to maintain product stability.

Storage Requirements

The unopened vials must be stored not above 25 C. To prevent degradation, the product must be kept in the outer carton in order to protect from light. From a stability perspective, the reconstituted solution should ideally be used immediately. If not used right away, the solution is stable for up to 24 hours when refrigerated at 2 C to 8 C.

All medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Nipogalin must be disposed of in accordance with local requirements. Disposal should utilize official drug take-back programs when available. If not, follow the recommended household procedure of mixing the medicine with an undesirable substance, sealing it in a container, and placing it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nipogalin found in:

A-Z Index: